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Abstract
Purpose: We investigated the etiology of acute hepatitis in three children with systemic Juvenile
Idiopathic Arthritis (sJIA) taking Interleukin-1 receptor antagonist (IL1RA).
Methods: Laboratory and clinical data for three children with sJIA diagnosed at ages 13 months to
8 years who developed acute hepatitis during treatment with IL1RA were reviewed for evidence
of sJIA flare, infection, macrophage activation syndrome (MAS), malignancy, and drug reaction.
Results: In all patients, hepatitis persisted despite cessation of known hepatotoxic drugs and in
absence of known infectious triggers, until discontinuation of IL1RA. Liver biopsies had mixed
inflammatory infiltrates with associated hepatocellular injury suggestive of an exogenous trigger. At
the time of hepatitis, laboratory data and liver biopsies were not characteristic of MAS. In two
patients, transaminitis resolved within one week of discontinuing IL1RA, the third improved
dramatically in one month.
Conclusions: Although sJIA symptoms improved significantly on IL1RA, it appeared that IL1RA
contributed to the development of acute hepatitis. Hepatitis possibly occurred as a result of an
altered immune response to a typical childhood infection while on IL1RA. Alternatively, hepatitis
could have represented an atypical presentation of MAS in patients with sJIA taking IL1RA. Further
investigation is warranted to determine how anti-IL1 therapies alter immune responsiveness to
exogenous triggers in patients with immune dysfunction such as sJIA. Our patients suggest that
close monitoring for hepatic and other toxicities is indicated when treating with IL1RA.
Background
sJIA is a systemic autoinflammatory disorder of unknown
etiology frequently characterized by quotidian fever, rash,
generalized lymphadenopathy, hepatosplenomegaly,
pericarditis and arthritis. Transaminitis, defined as eleva-
tion of hepatic enzymes (specifically alanine aminotrans-
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ferase (ALT) and aspartate aminotransferase (AST)) in the
absence of other clinical or laboratory evidence of hepatic
injury, can be seen in patients with sJIA either in disease
flares or due to hepatotoxic therapies like methotrexate
[1,2]. The mechanism by which patients develop sJIA is
unknown, but it is felt to involve the interaction of infec-
tious or inflammatory triggers with a genetic predisposi-
tion toward an enhanced proinflammatory response.
Cytokines, particularly Interleukin-1 (IL-1) and Inter-
leukin-6 (IL-6) have been implicated as important in dis-
ease pathogenesis and maintenance of inflammation
[1,2]. MAS is a complication of various rheumatologic
and infectious diseases, and is often associated with sJIA.
It is clinically characterized by cytopenias, disseminated
intravascular coagulation, hemodynamic instability and
liver and neurological involvement [3,4]. Hemophagocy-
tosis by activated macrophages is considered by most
authors to be the most specific histopathological feature
of MAS [3,4]. Hemophagocytosis is generally accompa-
nied by a lymphohistiocytic infiltrate including a predom-
inance of CD8+ lymphocytes [5] although some reports in
adults have additionally identified biliary injury and vas-
cular microthrombi as frequent findings [6]. Mortality
due to MAS has been estimated at 8-22% [3,7].
Non-steroidal anti-inflammatory drugs (NSAIDs) and sys-
temic corticosteroids have historically been the mainstays
of treatment for sJIA [1,2]. There is evidence that meth-
otrexate, cyclosporine, and etanercept are less effective in
sJIA than in other forms of juvenile arthritis, and some
disease-modifying drugs may be associated with develop-
ment of MAS [1,2]. IL-1 receptor antagonist (IL1RA) (ana-
kinra) and anti-IL-6 (MRA/tocilizumab) have shown
clinical efficacy in small open-label studies in sJIA and
adult Still's Disease [8-11]. MAS, which leads to the great-
est morbidity and mortality in patients with sJIA, is gener-
ally treated with supportive care, high dose intravenous
corticosteroids and other immunosuppressive agents.
MAS may also be treated with etoposide or cyclosporine
in a similar fashion to primary or familial hemophago-
cytic lymphohistiocytosis (HLH), a genetic disorder
related to alterations in cytotoxic granular release that can
be triggered by infections and neoplasms [12]. MAS is a
form of secondary HLH. There is a single case report of
successful treatment of MAS with IL1RA in a patient with
sJIA [13].
As many as 50-100% of patients with sJIA respond to
IL1RA [8,10,11]. Despite these promising case series, the
safety of IL1RA in large numbers of patients with sJIA has
not been established. Furthermore, the effects of IL-1
blockade on the inflammatory response of patients with
sJIA have not been formally studied. One case report sug-
gests IL1RA as a trigger for MAS in an adolescent with sJIA
[14]. In this case series we sought to investigate the extent
to which a significant adverse event, acute hepatitis, was
related to treatment with IL1RA in three patients with sJIA.
Patients and Methods
Three patients with sJIA, all treated at different tertiary care
pediatric centers, developed acute hepatitis while taking
IL1RA. All laboratory and clinical data were collected and
reviewed retrospectively (Table 1). All three patients had a
presentation of severe disease with significant arthritis
and persistently elevated inflammatory markers, but dif-
fered in age and ethnicity. All liver biopsies were reviewed
by a single hepatopathologist (SRN). The Colorado Mul-
tiple Institutional Review Board approved this series.
Results
After a thorough evaluation by a pediatric rheumatologist
led to the diagnosis of sJIA, all three patients were treated
with IL1RA in the first few months after diagnosis due to
severe or refractory disease (Table 1). Patients 2 and 3
were treated with IL1RA without prior methotrexate or
TNFα-inhibiting therapies, and both patients had received
treatment with high-dose IV corticosteroids in the month
preceding hepatitis. After development of abdominal pain
in all patients and jaundice in 2 patients, acute hepatitis
was diagnosed between 44 and 250 days after initiation of
IL1RA treatment. A thorough evaluation of each patient's
hepatitis ruled out common infectious and autoimmune
causes; although antecedent flu-like symptoms were
present in patient two, and fever/diarrhea in patient three.
Patient one had neither viral symptoms nor serologic evi-
dence of an infectious process or drug exposure; although
she had been treated with methotrexate until two weeks
prior to the development of hepatitis. Liver biopsies
showed a mixed inflammatory infiltrate without hemo-
phagocytosis or microthrombi, suggesting hepatocellular
injury due to an exogenous trigger. Two patients had sig-
nificant hyperbilirubinemia with increased serum direct
bilirubin (data not shown), without histological cholesta-
sis on liver biopsy. Elevation of cholestatic enzymes was
less impressive than transaminitis, and patient two had
normal measurements. Cessation of IL1RA resulted in
rapid improvement of liver enzymes, but two patients
experienced a sJIA flare, requiring pulse corticosteroid
therapy. Clinical suspicion for MAS was low, and bone
marrow biopsies were not performed. Liver biopsies
showed a nonspecific pattern of mixed inflammation
without identifiable hemophagocytosis, vascular micro-
thrombi, or cholestatic biliary injury. Staining for macro-
phage markers (CD68 and CD163) showed a mild to
moderate increase in the numbers of Kupffer cells, which
may represent a nonspecific reaction to hepatocyte injury
(Figure 1). Patient 1 also showed evidence of liver syn-
thetic dysfunction (prolongation of her PT) that improved
rapidly after cessation of IL1RA (Figure 2). Patient one
had no LFT elevations prior to treatment with IL1RA,Pediatric Rheumatology 2009, 7:21 http://www.ped-rheum.com/content/7/1/21
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while patient 2 had mild transaminitis with MAS just
prior to initiation of IL1RA, and patient 3 had multiple
bouts of transaminitis with flu-like illnesses both before
and after her acute hepatitis (Figure 2A). Thrombocytope-
nia and elevated ferritin, known markers of MAS, were
absent during the time period of acute hepatitis in all
patients (Figure 2B). Patient 1 and Patient 2 were restarted
on IL1RA for refractory disease, and have had no further
liver problems.
Discussion
This case series is illustrative of three children with sJIA
who developed acute hepatitis while being treated with
IL1RA. Clinical and laboratory data, as well as liver
biopsy, were not characteristic of MAS. Biopsies instead
suggested hepatocellular injury from an exogenous cause,
be it infectious or chemical (Figure 1). The presence of
eosinophils in two of the three liver biopsies may also
support an exogenous trigger contributing to the hepatitis.
A viral trigger may have contributed to development of
hepatitis in two patients, although serologies for viruses
known to induce hepatitis were negative (Table 1). We are
then left with a serious adverse event coincident with
IL1RA treatment and reversed upon discontinuation of
the drug. This suggests that IL-1 blockade contributed to
the development or propagation of these patients' liver
injury.
The clinical history of these patients underscores our lack
of understanding of the influence of IL-1 blockade on the
natural history of sJIA. Hepatitis could occur due to four
potentially overlapping mechanisms. First, pure drug tox-
icity from anakinra appears possible, but unlikely given
the absence of prior reports of hepatitis with anakinra
therapy, the variable time to onset of hepatitis, and the
tolerance of restarting IL1RA in two patients. Second,
induction of autoimmune hepatitis (AIH) by the use of a
biologic agent is possible, but also appears unlikely in the
absence of specific autoantibodies or histopathological
features associated with AIH. Third, immune dysregula-
tion induced by IL1RA in children with sJIA could lead to
hepatitis upon exposure to a normally benign infectious
or environmental trigger. Fourth, IL1RA could change the
clinical manifestations of MAS flare in some patients with
sJIA leading only to acute hepatitis instead of the full MAS
phenotype.
In vitro evidence suggests that inflammatory cytokines
have pleiotropic effects on hepatocytes that can influence
the development of hepatitis. Tumor necrosis factor recep-
tor 1 (TNFR1), which can be expressed on hepatocytes,
can signal through the TNFR-associated death domain
(TRADD) to induce caspase activation and apoptotic cell
death of hepatocytes [15]. Signaling through TNFR1 can
also lead to the formation of reactive oxygen species, sus-
tained c-Jun N-terminal kinase (JNK) activation and
apoptotic cell death via a caspase-independent mecha-
nism [16]. In contrast, signaling through TNFα and IL-6
receptors on hepatocytes can elicit signals that promote
liver regeneration [17,18]. These apparently contradictory
findings underscore our poor understanding of the roles
of cytokines in liver injury. IL1RA may change cytokine
production and response in patients with sJIA, and in a
subset of patients this could lead to direct effects on hepa-
tocyte apoptosis and the development of hepatitis.
This case series is important in that it is the first account of
acute hepatitis in children with sJIA treated with IL1RA.
Liver Biopsy results for three patients with SJIA and acute hepatitis Figure 1
Liver Biopsy results for three patients with SJIA and acute hepatitis. (A) Patient 1 hematoxylin and eosin (H&E) stain-
ing of liver biopsy. (B) Patient 2 H&E staining of liver biopsy with inset picture of the liver biopsy stained with anti-CD163 anti-
bodies (Kupffer cell marker) showing a moderate increase in sinusoidal macrophages. (C) Patient 3 H&E staining of liver biopsy 
with inset picture of the liver biopsy stained with anti-CD68 antibodies (macrophage marker) showing a mild increase in sinu-
soidal macrophages.Pediatric Rheumatology 2009, 7:21 http://www.ped-rheum.com/content/7/1/21
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Hepatitis appears to have occurred outside the context of
a sJIA flare or the development of MAS. The short half-life
of IL1RA may have been advantageous, since discontinu-
ation led to the rapid improvement of hepatitis. Newer IL-
1 blocking agents with longer half-lives could have a more
prolonged effect in susceptible patients with sJIA. Data in
patients with sJIA and Still's Disease are emerging that
support the efficacy and safety of IL-1 blockade, and use
of these treatments will likely expand [2,8,10,11]. Atten-
tion should be paid to possible hepatic side effects in clin-
ical trials and post-marketing safety studies. Frequent LFT
monitoring as well as the capacity for rapid reversal of IL-
1 blockade may be important in preventing liver damage
in some patients. This case series highlights the impor-
tance of more prospective studies such as the one recently
published by Gattorno et al to determine the influence of
IL-1 blockade on the cytokine networks in patients with
sJIA [19].
Summary of lab findings from three patients with sJIA and hepatitis Figure 2
Summary of lab findings from three patients with sJIA and hepatitis. Green = Pt. 1, Blue = Pt. 2, Red = Pt. 3. (A) AST 
(open circles) and PT (filled triangles) (B) Ferritin (open circles) and Platelets (filled triangles).Publish with BioMed Central    and   every 
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